However, as circulating CXCL10 and CXCL9 levels did not correlate with tumor lymphocyte counts, their analysis from the blood samples cannot be used as a biomarker for T-cell rich tumors, further highlighting the importance of analyzing cytokines in primary tumor samples. The gene discussed is CXCL9; the disease is neoplasm.